Zhejiang Starry Pharmaceutical Co., Ltd. (603520)

Overview

Zhejiang Starry Pharmaceutical Co.,Ltd. is an established entity in the pharmaceutical sector, renowned for its significant contributions in research and development, manufacturing, and distribution of pharmaceutical products, specifically in the areas of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates. Having commenced its operations in 1997, the company has made substantial strides in offering both domestic and international markets with innovative healthcare solutions. Headquartered in Taizhou, China, Zhejiang Starry Pharmaceutical stands as a testament to the country's capabilities in advancing medical science and technology on a global scale.

Products and Services

Zhejiang Starry Pharmaceutical offers a wide range of products catering to diverse needs within the pharmaceutical domain, especially focusing on the development of contrast agents and fluoroquinolones. Below is an outline of their primary offerings:

• Contrast Agent Products: Their portfolio includes notable substances such as iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate. These agents are pivotal in medical imaging, allowing for clearer visualization of internal body structures, thus facilitating more accurate diagnoses.
• Fluoroquinolones Products: This category comprises antibacterial drugs such as levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. Fluoroquinolones are vital in the treatment of a wide range of bacterial infections, offering a broad-spectrum antibiotic solution that has become essential in contemporary medicine.